# A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

> **NCT06764771** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 437 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** BMS-986488
- **DRUG:** Adagrasib
- **DRUG:** Cetuximab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06764771
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2027-10-15
- **Final completion:** 2027-10-15
- **Target enrollment:** 437 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764771, "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06764771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*